FDA Investigator Qiao Y Bobo
Qiao Y Bobo has conducted inspections on 12 sites in 6 countries as of 18 Jan 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
12
Last Inspection Date:
18 Jan 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Spain,
United States of America,
China,
United Kingdom of Great Britain and Northern Ireland,
Italy,
Germany
FDA Investigators that have inspected at least one site in common with Qiao Y Bobo:
Abby E Pelletier,
Alice C Silva,
Allison A Rodriguez,
Althea A Williams,
Ana S Cabrera,
Andrace L Deyampert,
Andrea D Swingle,
Angela K Shen,
Anissa M Cheung,
Ann Marie Montemurro,
Ann Marie Schofield,
Annemarie Bodnar,
Arie C Menachem,
Arsen Karapetyan,
Barbara M Frazier,
Bei Y He,
Benjamin J Smith,
Burnell M Henry,
Byungja E Marciante,
CDR Jeremy L Wally, PhD,
Chad R Burger,
Charles I Ann,
Charles L Zhou,
Charles Yuanchia Kuo, PhD,
Christian D Lynch (CDL),
Christina V Santos,
Christopher T Middendorf,
Constantin Y Philopoulos,
Corrine M Carter,
Creighton T Tuzon,
Cynthia Jim, CSO,
Daniel J Roberts,
Daniel T Lee,
David A Paterson,
Dawn L Wydner,
Debara R Reese,
Debara Reese,
Denise L Burosh,
Dennis E Guilfoyle, PhD,
Dina A Tallman,
Dolores Harper,
Donald C Obenhuber, PhD,
Dr. Gang Wang, PhD,
Dr. Guang Gao, PhD,
Dr. Ralph M Bernstein, PhD,
Eileen A Liu,
Elizabeth B Griffin,
Emest F Bizjak,
Emily J Orban,
Erin L Mcfiren,
Gene D Arcy,
Helen B Ricalde,
J David Doleski,
Jacob M Dyer,
Jacqueline Mdiaz Albertini,
Janet L Bowen,
Jean Blackston Hill,
Jean M Kelahan,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer A Kemp,
Jennifer Macmillan,
Jie He,
Joan A Loreng,
Joanne Pryzbylik,
Jonathan W Chapman,
José E Meléndez,
Joseph A Piechocki,
Joseph R Strelnik,
Joyce A Rockwell,
Jude C Dikes,
Julie D Bringger,
Justin A Boyd,
Karen M Montgomery (KMM),
Katherine Szestypalow,
Kelly I Anderson,
Kimberly M Bigler,
L'oreal F Walker,
Larry K Austin,
Lauren Iacono Connors, PhD,
Lauren M Lilly, PhD,
LCDR Debra Emerson,
Leigh Anne Myers,
Leiyun Boone, PhD,
Lindsey M Schwierjohann,
Lisa M Bellows,
Lori Peters,
Lori S Lawless,
Luella J Rossi,
Lynne M Dwyer,
Marie F Morin,
Marion Michaelis,
Mariza M Jafary,
Martha T Olone,
Mary T Carden,
Maura Rooney,
Meihong Liu,
Meisha R Sampson,
Meisha Waters,
Melina Lrodriguez Upton,
Mercy Oyugi,
Michael A Charles,
Michael Merchlinsky,
Michael Shanks, MS,
Michele L Forster, PhD,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Montgomery Montgomery, Karen M,
Muna Algharibeh,
Myra K Casey,
Nailing Zhang,
Nancy L Neiger,
Neali H Lucas,
Nicole K Trudel,
Nimmy Mathews,
Omotunde O Osunsanmi,
Patricia A Cochran,
Patricia D Gardner,
Patricia H Dlugosz,
Patrick B Cummings,
Patsy J Domingo,
Paula A Trost,
Peggy M Speight,
Peter E Baker,
Prabhu P Raju,
Prajakta A Varadkar,
Priscilla M Pastrana,
Rafeeq A Habeeb,
Ralph A Erickson,
Raymond T Oji,
Rebecca E Dombrowski,
Rebecca K Olin,
Richard D Manney,
Robert D Tollefsen,
Robert J Ham,
Robert M Barbosa,
Ronald T Nowalk,
Rose Ashley,
Roy Baby,
Sandra A Boyd,
Sandra P White,
Santos E Camara,
Sarah Forney,
Sharmila Shrestha,
Shawn E Larson,
Sheryl A Kochman,
Sidney B Priesmeyer,
Simone E Pitts,
Steven A Rubin,
Susan F Laska, MS,
Susan M Jackson,
Susan P Bruederle,
Susan T Hadman,
Suyang Qin,
Tammy L Chavis,
Teresita C Mercado,
Thai D Truong,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Tina M Pawlowski,
Unnee Ranjan,
Uttaniti Limchumroon (Tom),
Wayne E Seifert,
Wendy G Tan, PhD,
William D Tingley,
Xiaokuang Lai, PhD,
Yangmin Ning,
Yuan Chia Kuo,
Yumi J Hiramine,
Zhiping Ye, PhD
Qiao Y Bobo's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| July, 2012 | FDA 483 | Takeda Manufacturing Italia SPA - Form 483, 2012-07-25 |
| October, 2023 | FDA 483 | Eli Lilly and Company - Form 483, 2023-10-06 |
| January, 2024 | FDA 483 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Huanghe Road Site) - Form 483, 2024-01-16 |
| May, 2011 | FDA 483 | SmithKline Beecham Pharma GmbH & Co. KG (dba GlaxoSmithKline Biologicals) - Form 483, 2011-05-05 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more